Biodistribution analysis of cisplatin in liposomal form in animals with cisplatinresistant and cisplatin-sensitive carcinoma
Aim: To analyze the relation between pharmacokinetics of cisplatin in liposomal form and antitumor efficacy toward cisplatinresistant and cisplatin-sensitive variants of Guerin carcinoma. Concentration of platinum was measured by atomic absorption spectrophotometry (С115М1 “Selmi”, Ukraine). Elimina...
Gespeichert in:
| Veröffentlicht in: | Experimental Oncology |
|---|---|
| Datum: | 2010 |
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | Englisch |
| Veröffentlicht: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2010
|
| Schlagworte: | |
| Online Zugang: | https://nasplib.isofts.kiev.ua/handle/123456789/138591 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Назва журналу: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Zitieren: | Biodistribution analysis of cisplatin in liposomal form in animals with cisplatinresistant and cisplatin-sensitive carcinoma / M.M. Nosko, V.M. Pivnyuk, G.I. Solyanik, G.I. Kulik, I.N. Todor, V.Ya. Momot, O.R. Melnikov, O.V. Ponomareva, V.F. Chekhun // Experimental Oncology. — 2010. — Т. 32, № 1. — С. 40-43. — Бібліогр.: 14 назв. — англ. |
Institution
Digital Library of Periodicals of National Academy of Sciences of Ukraine| _version_ | 1862742963763806208 |
|---|---|
| author | Nosko, M.M. Pivnyuk, V.M. Solyanik, G.I. Kulik, G.I. Todor, I.N. Momot, V.Ya. Melnikov, O.R. Ponomareva, O.V. Chekhun, V.F. |
| author_facet | Nosko, M.M. Pivnyuk, V.M. Solyanik, G.I. Kulik, G.I. Todor, I.N. Momot, V.Ya. Melnikov, O.R. Ponomareva, O.V. Chekhun, V.F. |
| citation_txt | Biodistribution analysis of cisplatin in liposomal form in animals with cisplatinresistant and cisplatin-sensitive carcinoma / M.M. Nosko, V.M. Pivnyuk, G.I. Solyanik, G.I. Kulik, I.N. Todor, V.Ya. Momot, O.R. Melnikov, O.V. Ponomareva, V.F. Chekhun // Experimental Oncology. — 2010. — Т. 32, № 1. — С. 40-43. — Бібліогр.: 14 назв. — англ. |
| collection | DSpace DC |
| container_title | Experimental Oncology |
| description | Aim: To analyze the relation between pharmacokinetics of cisplatin in liposomal form and antitumor efficacy toward cisplatinresistant and cisplatin-sensitive variants of Guerin carcinoma. Concentration of platinum was measured by atomic absorption spectrophotometry (С115М1 “Selmi”, Ukraine). Elimination constant was calculated based on the dynamics of cisplatin concentration in time period between 1 h to 24 h using nonlinear regression analysis. Area under curve (AUC24) was calculated by the trapezium method. Results: It was shown that for liposomal form of cisplatin (LCp) AUC24 in tumor practically didn’t depend on the level of the tumor sensitivity, while in animals with the resistant variant (CpRGC), AUC24 for free cisplatin (FCp) decreased by 70% less (p < 0.001) as compared to the sensitive tumor strain (CpSGC). Significant decrease of elimination constant of LCp compared to FCp in blood serum of rats bearing either CpRGC or CpSGC tumors favors cisplatin accumulation in tumor tissues with low vascularization level. The dynamics of cisplatin concentration in CpRGC variant was characterized by 90% higher level in 24 h after administration of LCp as compared to FCp (p < 0.05). This fact may explain increased antitumor efficacy of LCp compared to FCp toward CpRGC variant. In the study of kidney function, AUC24 index for LCp was by 68.6% (p < 0.01) and 50.7% (p < 0.05) lower than AUC24 index for FCp in rats with CpRGC and CpSGC variants, respectively. No significant differences have been found in biodistribution of cisplatin in both pharmaceutical forms in liver and lung in CpRGC-r CpSGC-bearing rats. Conclusion: The results suggest that cisplatin in liposomal form possesses higher specificity of antitumor action than free cisplatin.
|
| first_indexed | 2025-12-07T20:27:57Z |
| format | Article |
| fulltext | |
| id | nasplib_isofts_kiev_ua-123456789-138591 |
| institution | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| issn | 1812-9269 |
| language | English |
| last_indexed | 2025-12-07T20:27:57Z |
| publishDate | 2010 |
| publisher | Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| record_format | dspace |
| spelling | Nosko, M.M. Pivnyuk, V.M. Solyanik, G.I. Kulik, G.I. Todor, I.N. Momot, V.Ya. Melnikov, O.R. Ponomareva, O.V. Chekhun, V.F. 2018-06-19T10:12:30Z 2018-06-19T10:12:30Z 2010 Biodistribution analysis of cisplatin in liposomal form in animals with cisplatinresistant and cisplatin-sensitive carcinoma / M.M. Nosko, V.M. Pivnyuk, G.I. Solyanik, G.I. Kulik, I.N. Todor, V.Ya. Momot, O.R. Melnikov, O.V. Ponomareva, V.F. Chekhun // Experimental Oncology. — 2010. — Т. 32, № 1. — С. 40-43. — Бібліогр.: 14 назв. — англ. 1812-9269 https://nasplib.isofts.kiev.ua/handle/123456789/138591 Aim: To analyze the relation between pharmacokinetics of cisplatin in liposomal form and antitumor efficacy toward cisplatinresistant and cisplatin-sensitive variants of Guerin carcinoma. Concentration of platinum was measured by atomic absorption spectrophotometry (С115М1 “Selmi”, Ukraine). Elimination constant was calculated based on the dynamics of cisplatin concentration in time period between 1 h to 24 h using nonlinear regression analysis. Area under curve (AUC24) was calculated by the trapezium method. Results: It was shown that for liposomal form of cisplatin (LCp) AUC24 in tumor practically didn’t depend on the level of the tumor sensitivity, while in animals with the resistant variant (CpRGC), AUC24 for free cisplatin (FCp) decreased by 70% less (p < 0.001) as compared to the sensitive tumor strain (CpSGC). Significant decrease of elimination constant of LCp compared to FCp in blood serum of rats bearing either CpRGC or CpSGC tumors favors cisplatin accumulation in tumor tissues with low vascularization level. The dynamics of cisplatin concentration in CpRGC variant was characterized by 90% higher level in 24 h after administration of LCp as compared to FCp (p < 0.05). This fact may explain increased antitumor efficacy of LCp compared to FCp toward CpRGC variant. In the study of kidney function, AUC24 index for LCp was by 68.6% (p < 0.01) and 50.7% (p < 0.05) lower than AUC24 index for FCp in rats with CpRGC and CpSGC variants, respectively. No significant differences have been found in biodistribution of cisplatin in both pharmaceutical forms in liver and lung in CpRGC-r CpSGC-bearing rats. Conclusion: The results suggest that cisplatin in liposomal form possesses higher specificity of antitumor action than free cisplatin. en Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України Experimental Oncology Original contributions Biodistribution analysis of cisplatin in liposomal form in animals with cisplatinresistant and cisplatin-sensitive carcinoma Article published earlier |
| spellingShingle | Biodistribution analysis of cisplatin in liposomal form in animals with cisplatinresistant and cisplatin-sensitive carcinoma Nosko, M.M. Pivnyuk, V.M. Solyanik, G.I. Kulik, G.I. Todor, I.N. Momot, V.Ya. Melnikov, O.R. Ponomareva, O.V. Chekhun, V.F. Original contributions |
| title | Biodistribution analysis of cisplatin in liposomal form in animals with cisplatinresistant and cisplatin-sensitive carcinoma |
| title_full | Biodistribution analysis of cisplatin in liposomal form in animals with cisplatinresistant and cisplatin-sensitive carcinoma |
| title_fullStr | Biodistribution analysis of cisplatin in liposomal form in animals with cisplatinresistant and cisplatin-sensitive carcinoma |
| title_full_unstemmed | Biodistribution analysis of cisplatin in liposomal form in animals with cisplatinresistant and cisplatin-sensitive carcinoma |
| title_short | Biodistribution analysis of cisplatin in liposomal form in animals with cisplatinresistant and cisplatin-sensitive carcinoma |
| title_sort | biodistribution analysis of cisplatin in liposomal form in animals with cisplatinresistant and cisplatin-sensitive carcinoma |
| topic | Original contributions |
| topic_facet | Original contributions |
| url | https://nasplib.isofts.kiev.ua/handle/123456789/138591 |
| work_keys_str_mv | AT noskomm biodistributionanalysisofcisplatininliposomalforminanimalswithcisplatinresistantandcisplatinsensitivecarcinoma AT pivnyukvm biodistributionanalysisofcisplatininliposomalforminanimalswithcisplatinresistantandcisplatinsensitivecarcinoma AT solyanikgi biodistributionanalysisofcisplatininliposomalforminanimalswithcisplatinresistantandcisplatinsensitivecarcinoma AT kulikgi biodistributionanalysisofcisplatininliposomalforminanimalswithcisplatinresistantandcisplatinsensitivecarcinoma AT todorin biodistributionanalysisofcisplatininliposomalforminanimalswithcisplatinresistantandcisplatinsensitivecarcinoma AT momotvya biodistributionanalysisofcisplatininliposomalforminanimalswithcisplatinresistantandcisplatinsensitivecarcinoma AT melnikovor biodistributionanalysisofcisplatininliposomalforminanimalswithcisplatinresistantandcisplatinsensitivecarcinoma AT ponomarevaov biodistributionanalysisofcisplatininliposomalforminanimalswithcisplatinresistantandcisplatinsensitivecarcinoma AT chekhunvf biodistributionanalysisofcisplatininliposomalforminanimalswithcisplatinresistantandcisplatinsensitivecarcinoma |